Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims data.

PubWeight™: 1.01‹?› | Rank: Top 15%

🔗 View Article (PMC 4014371)

Published in Int J Chron Obstruct Pulmon Dis on May 03, 2014

Authors

Christine L Baker1, Kelly H Zou1, Jun Su2

Author Affiliations

1: Pfizer Inc., New York, NY, USA.
2: Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.

Articles cited by this

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol (1992) 60.45

Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med (2006) 49.95

Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med (2009) 35.68

A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 17.19

The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43

Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med (2011) 7.92

Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 4.87

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med (2013) 4.22

COPD exacerbations: defining their cause and prevention. Lancet (2007) 3.46

Chronic obstructive pulmonary disease surveillance--United States, 1971-2000. Respir Care (2002) 3.02

Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J (2004) 2.80

Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2007) 2.69

The costs of treating COPD in the United States. Chest (2001) 2.43

A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med (2010) 1.92

The McNemar test for binary matched-pairs data: mid-p and asymptotic are better than exact conditional. BMC Med Res Methodol (2013) 1.73

Risk factors of hospitalization and readmission of patients with COPD exacerbation--systematic review. Int J Chron Obstruct Pulmon Dis (2007) 1.67

Life expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III Follow-up Study. Int J Chron Obstruct Pulmon Dis (2009) 1.57

Risk factors for hospital readmission in patients with chronic obstructive pulmonary disease. Respiration (2005) 1.56

Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J (2000) 1.49

Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. Int J Chron Obstruct Pulmon Dis (2012) 1.45

Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD (2012) 1.32

Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med (2006) 1.31

Risk assessment of readmissions following an initial COPD-related hospitalization. Int J Chron Obstruct Pulmon Dis (2013) 1.11

Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2013) 1.07

Characteristics of undertreatment in COPD in the general population. Chest (2013) 0.97

Factors affecting chronic obstructive pulmonary disease early rehospitalization. Chron Respir Dis (2012) 0.94

Analysis of hospitalizations for COPD exacerbation: opportunities for improving care. COPD (2010) 0.92

Outcomes associated with timing of maintenance treatment for COPD exacerbation. Am J Manag Care (2012) 0.84

How should we define and classify exacerbations in chronic obstructive pulmonary disease? Expert Rev Respir Med (2013) 0.83

Respiratory-related medical expenditure and inpatient utilisation among COPD patients receiving long-acting bronchodilator therapy. J Med Econ (2011) 0.81